Glucose-6-phosphate dehydrogenase deficiency screening
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency screening On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency screening |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency screening |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency screening |
|
Glucose-6-phosphate dehydrogenase deficiency screening in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency screening |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
|
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Overview
G6PD defeciency screening in neonates is done routinly in some regions with high incidence.
Screening
- G6PD defeciency screening in neonates is done routinly in some regions with high incidence. [1]
- Screening test is quantitative laboratory assay for G6PD enzyme activity.
- Screening is done before giving oxidant medication to high risk patients.
- There is insufficient evidence to recommend routine screening for G6PD deficiency.
References
- ↑ Kaplan M, Hammerman C (February 2009). "The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective". J Perinatol. 29 Suppl 1: S46–52. doi:10.1038/jp.2008.216. PMID 19177059.